Sign Up Today and Learn More About Eikon Therapeutics Stock
Invest in or calculate the value of your shares in Eikon Therapeutics or other pre-IPO companies through EquityZen's platform.
Eikon Therapeutics Stock (EITH)
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
About Eikon Therapeutics Stock
Founded
2019
Headquarters
Hayward, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Eikon Therapeutics is a biopharmaceutical company employing revolutionary technology at the interface of biology, engineering, and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes that enable real-time, molecular-resolution measurements of protein movement in living cells.
Eikon Therapeutics Press Mentions
Stay in the know about the latest news on Eikon Therapeutics
Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer
businesswire • Nov 20, 2024
Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
businesswire • Aug 05, 2024
Sourcing/Category Manager job with Eikon Therapeutics | 2922322
biospace • Jun 26, 2024
Manager, Study Start Up job with Eikon Therapeutics | 2921940
biospace • Jun 26, 2024
Electrical Engineering Technician job with Eikon Therapeutics | 2923714
biospace • Jun 26, 2024
Eikon Therapeutics Management
Leadership team at Eikon Therapeutics
Co-Founder
Luke Lavi
Co-Founder
Xavier Darzacq
Join now and verify your accreditation status to gain access to:
- Eikon Therapeutics current valuation
- Eikon Therapeutics stock price
- Available deals in Eikon Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Eikon Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Eikon Therapeutics through EquityZen funds. These investments are made available by existing Eikon Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Eikon Therapeutics stock?
Shareholders can sell their Eikon Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."